As a country with a high incidence of hepatitis B, hepatitis B is often at the top of the infectious disease epidemic list. Experts believe that under the current state of drug treatment, the most fundamental hepatitis B treatment strategy is standardization. The hepatitis B virus has the characteristic of mutation and is prone to drug resistance, thus making chronic hepatitis B difficult and complex to treat, so standardized treatment is especially important. Adherence to the principles of early treatment, regular review, lifelong monitoring, long-term intermittent targeted therapy, and comprehensive treatment is key. For example, for patients with positive HBVDNA but normal or mildly abnormal transaminases, it is best to perform liver biopsy and take a series of measures such as antiviral therapy, or liver-protective and anti-inflammatory therapy, or anti-liver fibrosis therapy, or temporary no-drug therapy and close observation of changes in the condition according to liver histopathological results. For inactive surface antigen carriers with normal liver function and negative HBVDNA, they should be re-examined every 6-12 months, and if necessary, ultrasound examinations should be performed to keep up with changes in their condition. Experts emphasize that patients with hepatitis B should avoid random use of drugs without indications, blind combination of drugs, blindly increasing the dose, reducing the dose or stopping the drugs at will. New antiviral drugs are being pioneered and gradually marketed, and research on treatment to regulate the immune status of the body is developing. The research on optimal treatment of chronic hepatitis B, standardized treatment, and hepatitis B virus mutation resistance is a major project of the National Eleventh Five-Year Plan, and it is believed that the prospect of treatment of chronic hepatitis B is broad.